Abstract
The peptidyl prolyl cis/trans isomerase Pin1, the human ortholog of yeast Ess1 specifically isomerizes peptide bindings of pSer/pThr-Pro residues in various proteins, and regulates the expression levels and functions of phosphorylated proteins. Activation of Pin1 is associated with pathology of a variety of diseases, such as cancer, Alzheimer’s disease, infectious diseases and so on. Therefore, regulatory compounds for Pin1 can be applied as a clinical medicine against these diseases. Many chemists have exerted themselves to synthesize the inhibitors based on the 3D structure of Pin1. We have screened for the inhibitors against Pin1 from the natural products including the functional foods. Here we review the Pin1-associated pathology and the known inhibitors identified from natural products. And we introduce the screening methods targeting Pin1 activity.
Keywords: Inhibitor, natural products, Pin1, screening.
Current Drug Targets
Title:Role of Prolyl Isomerase Pin1 in Pathogenesis of Diseases and Remedy for the Diseases from Natural Products
Volume: 15 Issue: 10
Author(s): Katsuhiko Takahashi, Taiki Shimizu, Keita Kosaka, Masafumi Hidaka, Chiyoko Uchida and Takafumi Uchida
Affiliation:
Keywords: Inhibitor, natural products, Pin1, screening.
Abstract: The peptidyl prolyl cis/trans isomerase Pin1, the human ortholog of yeast Ess1 specifically isomerizes peptide bindings of pSer/pThr-Pro residues in various proteins, and regulates the expression levels and functions of phosphorylated proteins. Activation of Pin1 is associated with pathology of a variety of diseases, such as cancer, Alzheimer’s disease, infectious diseases and so on. Therefore, regulatory compounds for Pin1 can be applied as a clinical medicine against these diseases. Many chemists have exerted themselves to synthesize the inhibitors based on the 3D structure of Pin1. We have screened for the inhibitors against Pin1 from the natural products including the functional foods. Here we review the Pin1-associated pathology and the known inhibitors identified from natural products. And we introduce the screening methods targeting Pin1 activity.
Export Options
About this article
Cite this article as:
Takahashi Katsuhiko, Shimizu Taiki, Kosaka Keita, Hidaka Masafumi, Uchida Chiyoko and Uchida Takafumi, Role of Prolyl Isomerase Pin1 in Pathogenesis of Diseases and Remedy for the Diseases from Natural Products, Current Drug Targets 2014; 15 (10) . https://dx.doi.org/10.2174/1389450115666140903110724
DOI https://dx.doi.org/10.2174/1389450115666140903110724 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Mesothelioma - Epidemiology and Management
Current Respiratory Medicine Reviews Editorial (Hot Topic: Computer-Aided Drug Design, Synthesis and Evaluation of New Anti-Cancer Drugs)
Current Topics in Medicinal Chemistry PEGylation of Proteins and Liposomes: a Powerful and Flexible Strategy to Improve the Drug Delivery
Current Drug Metabolism Flavonoids and other Non-alkaloidal Constituents of Genus Erythrina: Phytochemical Review
Combinatorial Chemistry & High Throughput Screening Myelodysplastic Syndromes: Review of Pathophysiology and Current Novel Treatment Approaches
Current Cancer Drug Targets DNA Double Strand Break Repair - Related Synthetic Lethality
Current Medicinal Chemistry HAART-Persistent HIV-1 Latent Reservoirs: Their Origin, Mechanisms of Stability and Potential Strategies for Eradication
Current HIV Research Growth Responses Following a Single Intra-Muscular hGH Plasmid Administration Compared to Daily Injections of hGH in Dwarf Mice
Current Gene Therapy Network Pharmacology of Ayurveda Formulation <i>Triphala</i> with Special Reference to Anti-Cancer Property
Combinatorial Chemistry & High Throughput Screening Small Molecules as Anti-TNF Drugs
Current Medicinal Chemistry Romidepsin (FK228), A Histone Deacetylase Inhibitor and its Analogues in Cancer Chemotherapy
Current Medicinal Chemistry Anti-angiogenic Treatment in Metastatic Colorectal Cancer: Current Issues and Future Aims
Current Cancer Therapy Reviews Crocetin: an Agent Derived from Saffron for Prevention and Therapy for Cancer
Current Pharmaceutical Biotechnology A Comprehensive Overview of Colon Cancer- A Grim Reaper of the 21st Century
Current Medicinal Chemistry Design Strategies, Structures and Molecular Interactions of Small Molecule Src Inhibitors
Anti-Cancer Agents in Medicinal Chemistry CD133+ Glioblastoma Stem-Like Cells Induce Vascular Mimicry in Vivo
Current Neurovascular Research Drug Coated Clay Nanoparticles for Delivery of Chemotherapeutics
Current Nanoscience Recent Advances in Validating MDM2 as a Cancer Target
Anti-Cancer Agents in Medicinal Chemistry α-Halogenoacrylic Derivatives of Antitumor Agents
Mini-Reviews in Medicinal Chemistry A Review on Hemisynthesis, Biosynthesis, Biological Activities, Mode of Action, and Structure-Activity Relationship of Podophyllotoxins: 2003- 2007
Current Medicinal Chemistry